SCHEMBL4111027

SCHEMBL4111027

CCOC(=O)c1ccc(NC(=O)Nc2cccc(OC(F)F)c2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.67
MAPT P10636 11/20 0.64
MEN1 O00255 8/20 0.64
KMT2A Q03164 8/20 0.64
CASP3 P42574 1/20 0.64
SENP7 Q9BQF6 1/20 0.64
SMN1; SMN2 Q16637 6/20 0.62
NPC1 O15118 5/20 0.62
RAB9A P51151 5/20 0.62
GAA P10253 1/20 0.58
LMNA P02545 2/20 0.57
NPSR1 Q6W5P4 2/20 0.57
HTT P42858 1/20 0.57
CA12 O43570 2/20 0.56
CA1 P00915 2/20 0.56
CA2 P00918 2/20 0.56
CA9 Q16790 2/20 0.56
USP2 O75604 1/20 0.55
MAPK1 P28482 1/20 0.55
ALDH1A1 P00352 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4117383 0.92 RAB9A (0.67) TRPV1MAPTMEN1KMT2ACASP3
SCHEMBL4122995 0.89 MAPT (0.74) TRPV1MAPTMEN1KMT2ACASP3
SCHEMBL4107148 0.89 TRPV1 (0.68) TRPV1MAPTMEN1KMT2ACASP3
SCHEMBL4112564 0.89 MEN1 (0.68) TRPV1MAPTMEN1KMT2ACASP3
SCHEMBL4111493 0.88 MAPT (0.67) MAPTMEN1KMT2ACASP3SENP7
SCHEMBL4122551 0.86 MAPT (0.72) TRPV1MAPTMEN1KMT2ACASP3
SCHEMBL4111990 0.86 MAPT (0.77) TRPV1MAPTMEN1KMT2ACASP3
SCHEMBL4115720 0.85 MAPT (0.74) MAPTMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL4106008 0.84 NPC1 (0.65) MAPTMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL4112123 0.84 ALDH1A1 (0.63) MAPTMEN1KMT2ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 TRPV1 169/4885MAPT 1654/4885MEN1 3273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.